Melodie Young NP and Andrea Nguyen, PA discuss handling prior authorizations for systemic therapies in AD.
This is a video synopsis/summary of a panel discussion involving Melodie Young, NP, and Andrea Nguyen, PA.
Experts discuss the selection and dosing of various biologic and JAK (Janus kinase) inhibitor therapies for patients. The speaker emphasizes flexibility in choosing therapies based on individual patient needs and issues. She highlights the importance of considering dosing flexibility, especially for patients well-controlled on a particular regimen. Andrea mentions instances where she adjusts dosages based on patient reactions or issues, achieving a balance between disease control and minimizing unwanted effects.
The conversation touches on the challenges of combining topical therapies with systemic injectables and oral JAK inhibitors, with the speaker expressing a preference for not combining topical and oral JAK inhibitors. The speaker acknowledges the complexity of insurance coverage and the need to navigate payer restrictions when prescribing therapies. Both practitioners discuss the art of medicine in tailoring treatments to individual patients, including dose escalation and the impact of prior authorization paperwork on clinical practice. They underscore the significant positive impact that effective treatments can have on patients' lives, making follow-up visits rewarding despite the initial workload. The discussion emphasizes the ongoing effort to optimize therapies for better patient outcomes in the context of managing chronic skin conditions.
Video synopsis is AI-generated and reviewed by HCPLive editorial staff.